The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU® (Trastuzumab Deruxtecan, T-DXd) versus physician’s choice of chemotherapy in hormone receptor-positive metastatic breast cancer patients.
Study Overview: Dr. Aditya Bardia presented the findings from DESTINY-Breast06, a Phase 3 trial that included patients with HER2-low and HER2-ultra-low metastatic breast cancer who progressed rapidly on prior first-line endocrine therapy. Patients were randomized to receive either ENHERTU® or standard chemotherapy options.
Key Findings:
- Efficacy: ENHERTU® showed a hazard ratio of approximately 0.38 for progression-free survival compared to the control group, with a median PFS of over 12 months.
- Mechanism: The drug targets HER2, delivering a payload to cancer cells, which could explain its effectiveness in this specific subgroup of patients.
- Consistent Performance: ENHERTU® maintained its efficacy regardless of previous CDK4/6 inhibitor treatment duration.
Safety Profile:
- Side Effects: Common side effects observed included nausea and myelosuppression.
- Serious Considerations: There was also a reported risk of pneumonitis, albeit rare, associated with ENHERTU® treatment.
Quality of Life: The study indicated that ENHERTU® could potentially enhance quality of life by controlling disease progression, with a response rate over 50%.
Broader Implications:
- Treatment Strategy: These results suggest that ENHERTU® might be considered earlier in the treatment pathway for suitable patients.
- HER2 Expression Versatility: The drug’s effectiveness in patients with very low HER2 expression broadens its potential application.
Conclusion: The DESTINY-Breast06 trial, as presented at SABCS 2024, provides evidence that ENHERTU® (Trastuzumab Deruxtecan, T-DXd) offers a favorable outcome over standard chemotherapy in certain metastatic breast cancer cases, though it comes with its own set of risks that must be carefully managed.
https://www.uclahealth.org/news/release/internationally-renowned-oncologist-lead-breast-cancer
